Nippon Kayaku And Teva Get Approval For Jointly Developed Filgrastim Biosimilar G-CSF
This article was originally published in PharmAsia News
Executive Summary
Nippon Kayaku and Teva Pharmaceuticals attained approval for the sale of their new jointly developed G-CSF Filgrastim biosimilar, the companies announced on Feb. 28